elevidys sarepta - Search News

Order byBest matchMost fresh

Sarepta shares crash

Top News

Impacts

Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy

Sarepta Therapeutics stock plummeted Monday after the company said a second patient receiving its gene therapy died from liver failure, raising serious questions on the drug’s outlook.Shares fell 40% to $21.

BioSpace · 1d

UPDATE: Second Patient Dies After Receiving Sarepta’s DMD Gene Therapy Elevidys

· 1d · on MSN

Biotech pauses trial after second patient death linked to gene therapy

· 1d

Second patient death reported with gene therapy for muscular dystrophy

The second death, like an earlier one reported in March, occurred in a teenage boy who suffered a fatal case of acute liver injury, a known side effect of the therapy.

· 1d

Sarepta crashes after second death linked to Roche-partnered Elevidys

· 1d

Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom

1don MSN

Sarepta downgraded as company suspends guidance after latest Elevidys death

Wall Street analysts were quick to downgrade Sarepta Therapeutics (NASDAQ:SRPT) on Monday as the company suspended its revenue guidance for 2025 following a second fatality linked to Elevidys, its gene therapy for Duchenne muscular dystrophy.

Business Wire1d

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS

Managed Healthcare Executive1d

Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients

A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys.

Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity

Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an analysis of SRPT stock now.

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

Why Sarepta Therapeutics (SRPT) Stock Is Down Today

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a second death linked to its Duchenne muscular dystrophy gene therapy. Elevidys.